Jannati, Ali
Toro-Serey, Claudio
Gomes-Osman, Joyce
Banks, Russell
Ciesla, Marissa
Showalter, John
Bates, David
Tobyne, Sean
Pascual-Leone, Alvaro
Article History
Received: 14 August 2023
Accepted: 4 December 2023
First Online: 2 January 2024
Declarations
:
: The study was explained to participants verbally and through written informed consent that was approved by the local IRB of each site participating in the GAP consortium (see the Bio-Hermes study website [CitationRef removed] for a list of study sites). If, in the opinion of the site principal investigator, the participant did not have the capacity to sign the informed consent form, a legally authorized representative was used to grant consent on behalf of the participant.
: The manuscript does not contain any individual person’s data in any form.
: APL is a co-founder and Chief Medical Officer of Linus Health and a co-founder of TI Solutions and declares ownership of shares or share options in the company. APL serves as a paid member of the scientific advisory boards for Neuroelectrics, Magstim Inc., TetraNeuron, Skin2Neuron, MedRhythms, and Hearts Radiant. DB is a co-founder and Chief Executive Officer of Linus Health and declares ownership of shares or share options in the company. JS is Chief Product Officer of Linus Health and declares ownership of shares or share options in the company. All other authors are employees of Linus Health and declare ownership of shares or share options in the company.